Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 28 results for ibs

  1. Irritable bowel syndrome in adults: diagnosis and management (CG61)

    This guideline covers diagnosing and managing irritable bowel syndrome (IBS) in people aged 18 and over. It details how to accurately diagnose IBS, and aims to improve the quality of life for adults with IBS by promoting effective management using dietary and lifestyle advice, pharmacological therapy and referral for psychological interventions.

    Clinical guideline
    Last updated
    4 April 2017
    View recommendations

    Sections for CG61

  2. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    11 February 2016
    View quality statements

    Sections for QS114

  3. Irritable bowel syndrome

    All NICE products on irritable bowel syndrome. Includes any guidance and quality standards.

    Topic page

  4. Ovarian cancer: recognition and initial management (CG122)

    This guideline covers detecting, diagnosing and treating women (aged 18 and older) who have, or are suspected of having, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or borderline ovarian cancer. It aims to enable earlier detection of ovarian cancer and improve initial treatment.

    Clinical guideline
    Last updated
    2 October 2023
    View recommendations

    Sections for CG122

  5. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)

    Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).

    HealthTech guidance
    Published
    2 October 2013
    View recommendations

    Sections for HTG320

  6. Refractory [Irritable bowel syndrome] (IBS):- What factors contribute to refractory IBS?

    CG61/3 Question Refractory [Irritable bowel syndrome] (IBS):- What factors contribute to refractory IBS? Any...

    Research recommendation
    Published
    9 June 2015

  7. SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (HTG598)

    Evidence-based recommendations on SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea.

    HealthTech guidance
    Published
    17 November 2021
    View recommendations

    Sections for HTG598

  8. Relaxation and biofeedback:- What is the effect of relaxation and biofeedback therapies on [Irritable bowel syndrome] (IBS) symptoms and patient-related outcomes?

    What is the effect of relaxation and biofeedback therapies on [Irritable bowel syndrome] (IBS) symptoms and patient-related...

    Research recommendation
    Published
    9 June 2015

  9. Psychological interventions:- Are the psychological interventions [cognitive behavioural therapy] (CBT), hypnotherapy and psychological therapy all equally effective in the management of [Irritable bowel syndrome] (IBS) symptoms, either as first-line therapies in primary care, or in the treatment of people with IBS that is refractory to other treatments?

    management of [Irritable bowel syndrome] (IBS) symptoms, either as first-line therapies in primary care, or in the...

    Research recommendation
    Published
    9 June 2015

  10. Herbal medicines:- Are Chinese and non-Chinese herbal medicines safe and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is the most effective and safe option?

    safe and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is the most...

    Research recommendation
    Published
    9 June 2015

  11. Research is needed to establish the efficacy and tolerability of bile acid sequestrants among people with irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection.

    and tolerability of bile acid sequestrants among people with irritable bowel syndrome (IBS-D) or Crohn's disease without...

    Research recommendation
    Published
    9 June 2015

  12. Research is needed to establish the nature of bile acid malabsorption and whether bile acid malabsorption is a primary or secondary condition in people diagnosed with irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection.

    is a primary or secondary condition in people diagnosed with irritable bowel syndrome (IBS-D) or Crohn's disease without...

    Research recommendation
    Published
    9 June 2015

  13. Research is needed to establish the validity and accuracy of the SeHCAT (tauroselcholic [75selenium] acid) test and of any potential alternative technologies for measuring bile acid malabsorption in people with chronic diarrhoea diagnosed with irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection.

    malabsorption in people with chronic diarrhoea diagnosed with irritable bowel syndrome (IBS-D) or Crohn's disease without...

    Research recommendation
    Published
    9 June 2015

  14. Suspected cancer: recognition and referral (NG12)

    This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.

    NICE guideline
    Last updated
    1 May 2025

    Sections for NG12

  15. Coeliac disease (QS134)

    This quality standard covers recognising, assessing and managing coeliac disease in adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    19 October 2016
    View quality statements

    Sections for QS134